Pazopanib in Second-line Therapy in Renal Cell Carcinoma (Q63315578)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pazopanib in Second-line Therapy in Renal Cell Carcinoma |
clinical trial |
Statements
A Phase II, Opened, Not Controlled and Multicentric Clinical Trial of Pazopanib in Monotherapy to Determine Efficiency and Safety in Second-line of Treatment in Patients With Carcinoma of Advanced Renal Cells That Have Progressed or Have Not Tolerated the First Line of Treatment With Tyrosine Kinase Inhibitor (English)
0 references
April 2012
0 references
October 2014
0 references
27
0 references
18 year
0 references